FLT3 and acute myeloid leukemia: Gilteritinib monotherapy prolonged survival (9.3 months vs. 5.6 months) compared with conventional salvage therapy (e.g., mitoxantrone, etoposide, and cytarabine (MEC); fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA); low-dose cytarabine (LDAC); and azacitidine) in patients with relapsed/refractory FLT3-mutated AML in the randomized phase 3 ADMIRAL trial [115].